Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunomedics (IMMU) - moderated -- Ignore unavailable to you. Want to Upgrade?

To: zevenhuizen who wrote (7787)	10/9/2009 10:02:02 AM
From: gonnahappensoon	Respond to of 63329

We needed to raise money and should have raised some at 6 bucks...IF we could have...I am not so sure we could though.

To: zevenhuizen who wrote (7787)	10/9/2009 11:12:01 AM
From: idahoranch1	Respond to of 63329

I got my monthly stock purchase this morning. I don't worry or concern myself with what it does this afternoon or next week. While there are still some news worthy events coming, V mab in ITP at ASH among others, and hopefully we still get the data for E-mab, I think most of us know that the big deal is hPAM4 at ASCO GI in January. Since the company is reported they've enrolled 24 patients as of a few weeks ago, they should have 30 or more to report on at ASCO-GI. It takes 3 months to treat and do the 8 week evaluation, which seems to be what they key on. So any patients they treat within two weeks should have the 8 week data available at ASCO-GI and any up through the middle of November should have the 4 week follow up data to report on. ASCO-GI is by far the biggest and most important conference for IMMU in its history. The data we've seen so far should be confirmed there, and with a significant number of patients at the higher doses, 12mc and 15 mc. Patients are responding, we know that (those of us who pay attention). The bar is low and the responses seem high, and we are in control, no partner to be concerned about. I'll repeat, hPAM4 will be the biggest biotech story of 2010.